Treatment of Osteogenesis Imperfecta with Parathyroid hormone and Zoledronic acid
TOPaZ is a randomised open-label clinical trial for people with osteogenesis imperfecta (OI). The study aims to investigate whether a two-year spell of treatment with a drug called teriparatide (TPTD) followed by treatment with another drug called Zoledronic acid (ZA) reduces the risk of broken bones occurring in people with OI.
Chief Investigator: Prof. Stuart Ralston
Number and location of participating sites (by region/ country): 25 UK and Republic of Ireland sites
EudraCT number: 2016-003228-22
ISRCTN number: 15313991
Funder: NIHR Efficacy and Mechanism Evaluation Programme
Start and End date:
Of grant award - Nov 2016-April 2023
Of recruitment - June 2017
Current Status: Recruiting (in small number of sites initially)
Trial Website: The TOPaZ Trial
GDPR Privacy Statement: If you have participated in this study and would like to read how it complies with GDPR, please read this document.
Sponsor: ACCORD http://www.accord.ed.ac.uk/
Chief Investigator: Professor Stuart Ralston, Molecular Medicine Centre, Institute of Genetics and Molecular Medicine, Western General Hospital, Edinburgh, EH4 2XU
Trial manager: Dr Holly Ennis (firstname.lastname@example.org)
ECTU Involvement: Trial management / Statistics / Database and randomisation service provision.